Oritavancin: a new avenue for resistant Gram-positive bacteria. Issue 3 (June 2005)

• Record Type: Journal Article
• Authors: Mercier, Renee-Claude; Hrebickova, Lenka
• Is Part Of: Expert review of anti-infective therapy. Volume 3:Issue 3(2005)
• Page Start: 325
• Page End: 332
• Publication Date: 2005-06
• Subjects: antimicrobial agent -- bacterial resistance -- enterococci -- glycopeptide -- Gram-positive bacteria -- staphylococci; Anti-infective agents -- Research -- Periodicals; 616.90461
• DOI: 10.1586/14787210.3.3.325
• Languages: English
• ISSNs: 1478-7210

Abstract

Oritavancin, a new semisynthetic glycopeptide has a spectrum of activity similar to vancomycin, although it exhibits potent antimicrobial activity against vancomycin-resistant staphylococci and enterococci species. It has a long-terminal half-life of 360 h, is highly protein bound and has been dosed once-daily in clinical trials. Oritavancin has been studied in complicated skin and skin structure infections where it was noninferior to the comparator group of vancomycin/cephalexin. Thus far, oritavancin has a favorable side-effect profile and appears promising in the treatment of multidrug resistant Gram-positive bacteria.